Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · October 17, 2023

Association of the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors With the Risk of Thyroid Cancer in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study
Diabetes Obes Metab 2023 Sep 21;[EPub Ahead of Print], S Bea, H Son, JH Bae, SW Cho, JY Shin, YM Cho

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading